Closing the Diagnostic Gap in Cancer Care.

GapScore’s platform reveals hidden vulnerabilities in tumor DNA replication to guide targeted, effective cancer treatments.

GapScore is developing the first functional cancer biomarker that directly detects single-stranded DNA (ssDNA) replication gaps — a core vulnerability exploited by modern therapies.

By measuring these previously overlooked defects in DNA integrity, GapScore reveals how a tumor is likely to respond to PARP inhibitors, platinum chemotherapy, and replication stress–targeting drugs.

This new biomarker enables clinicians and researchers to tailor treatment strategies to each tumor’s functional DNA repair profile — improving effectiveness while avoiding unnecessary toxicity.

GapScore, Inc.

Org chart

Teams

Offices